News

Filter

Current filters:

PharmaceuticalOncology

1 to 9 of 2162 results

Helsinn links with Mundipharma to commercialize anamorelin in China

26-03-2015

Exclusive agreement broadens Helsinn’s existing partnerships for anamorelin in the area of cancer supportive…

anamorelinChinaHelsinnLicensingMundipharmaOncologyPharmaceutical

Batch of mixed NICE decisions for Xarelto, Imnovid, Jardiance and Targaxan

25-03-2015

The National Institute of Health and Care Excellence (NICE), the medicines cost watchdog for England…

BayerBoehringer IngelheimCardio-vascularCelgene CorpDiabetesImnovidJardianceNephrology and HepatologyNorgineOncologyPharmaceuticalTargaxanUKXarelto

New enzalutamide presented by Astellas and Medivation at EAU

24-03-2015

Japanese pharma major Astellas Pharma and US drugmaker Medivation have presented new data from the Phase…

Astellas PharmaenzalutamideMedivationOncologyPharmaceuticalResearchXtandi

97% of Australians want new cancer medicines subsidized through PBS

24-03-2015

New findings released by Newspoll shows overwhelming support for access to new cancer medicines through…

AustraliaFinancialHealthcareOncologyPharmaceutical

Russia’s R-Pharm in deals with AbbVie and Bristol-Myers for local production

21-03-2015

US drugmaker AbbVie has joined forces with Russia’s R-Pharm to establish the joint production of Kaletra…

AbbVieAnti-viralsBristol-Myers SquibbKaletra TabletsOncologyPharmaceuticalProductionR-PharmRussiaSprycel

Lilly and Innovent collaborate to bring potential cancer drugs to market

20-03-2015

US pharma major Eli Lilly has joined forces with Innovent Biologics, a leading Chinese biotech firm,…

ChinaEli LillyGlobalInnovent BiologicsLicensingOncologyPharmaceuticalResearch

Nektar Therapeutics stock falls as NKTR-102 fails Phase III breast cancer study

Nektar Therapeutics stock falls as NKTR-102 fails Phase III breast cancer study

19-03-2015

Nektar Therapeutics has announced that its Phase III study of NKTR-102 (etirinotecan pegol) in advanced…

Nektar TherapeuticsNKTR-102OncologyPharmaceuticalResearch

Zeltia poised for significant potential growth, Edison raises valuation

Zeltia poised for significant potential growth, Edison raises valuation

18-03-2015

Spanish pharma company Zeltia is laying the groundwork for a period of significant potential growth and…

Business FinanceOncologyPharmaceuticalSpainYondelisZeltia

1 to 9 of 2162 results

Back to top